Description
Testagen (KEDG)
- A synthetic tetrapeptide (Lys-Glu-Asp-Gly) belonging to the Khavinson-class of short-peptide bioregulators, originally derived from analysis of testicular tissue extracts by Prof. Vladimir Khavinson’s research group. American Peptides
- Classified as an endogenous peptide modulator rather than a hormone — it’s studied for its potential to interact with cellular signaling pathways that govern testosterone production, rather than supplying exogenous hormone directly. It is not an androgen or testosterone itself. Newtropin
- Proposed to act through the hypothalamic-pituitary-gonadal (HPG) and hypothalamic-pituitary-thyroid (HPT) axes, influencing genes involved in pituitary signaling and downstream endocrine responses — including effects on TSH and testosterone biosynthesis via Leydig cell activity. Newbiorx
- Theoretically distinct from testosterone replacement therapy (TRT): TRT supplies exogenous hormone directly and can suppress the body’s own HPG axis and fertility, whereas Testagen is theorized to support the testicular tissue’s own endogenous function without shutting down that feedback loop. Newtropin
- Regulatory/evidence status: it’s marketed as a research/bioregulatory peptide with limited high-quality human evidence by U.S. standards, and it should not be treated as an approved testosterone therapy or fertility treatment. It’s typically sold explicitly for in-vitro research use only, not for use in humans or animals.
